Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review

References

• Williams WH, Evans JJ. Brain injury and emotion: an overview to a special issue on biopsychosocial approaches in neurorehabilitation. Neuropsychol Rehabil. 2003;13(1–2):1–11. doi:10.1016/S0960-9822(02)01374-X. Cited in PubMed: PMID: 22004099.
   PubMed Web of Science ®Google Scholar
• Eslinger PJ, Geder L. Behavioral and emotional changes after focal frontal lobe damage. In: Bogousslavsky J, Cummings JL, editors. Behavior and mood disorders in focal brain lesions. Cambridge: Cambridge University Press; 2000. p. 217–60.
   Google Scholar
• Deb S, Lyons I, Koutzoukis C. 1999. Neurobehavioural symptoms one year after a head injury. Br J Psychiatry 174:360–65. Cited in PubMed: PMID:10533556.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG. 1993. Apathy following cerebrovascular lesions. Stroke 24:1625–30. Cited in PubMed: PMID: 8236333.
   PubMed Web of Science ®Google Scholar
• Angelelli P, Paolucci S, Bivona U, Piccardi L, Ciurli P, Cantagallo A, Antonucci G, Fasotti L, Di Santantonio A, Grasso MG, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110:55–63. doi:10.1111/j.1600.0447.2004.00297.x. Cited in PubMed: PMID: 15180780.
   PubMed Web of Science ®Google Scholar
• Tateno A, Jorge RE, Robinson RG. Clinical correlates of aggressive behavior after traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2003;15:155–60. doi:10.1176/jnp.15.2.155. Cited in PubMed: PMID: 12724455.
   PubMed Web of Science ®Google Scholar
• Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143:35–39. doi:10.1176/ajp.143.1.35. Cited in PubMed: PMID: 3942284.
   PubMed Web of Science ®Google Scholar
• Azouvi P, Jokic C, Attal N, denys P, Bussel B. 1999. Carbamazepine in agitation and aggressive behaviour following severe closed head injury: results of an open trial. Brain Inj 13:797–804. Cited in PubMed: PMID: 10576463.
   PubMed Web of Science ®Google Scholar
• Ashman TA, Gordon WA, Contor JB, Hibbard MR. Neurobehavioral consequences of brain injury. Mount Sinai J Med. 2006;73:999–1005. Cited in PubMed: PMID: 17195886.
   PubMed Web of Science ®Google Scholar
• Sander AM. Brain injury and the family. Neurorehabilitation. 2007;22:1–2.
   Web of Science ®Google Scholar
• Alves Gavao MG, Rocha Crispino Santos MA, Alves Da Cunha MJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. 2014 Nov 21;11:CD002745. doi: 10.1002/14651858.CD002745. Cited in PubMed: PMID: 25415374
   Google Scholar
• Crosby N, Deane AH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;1:CD003468. doi:10.1002/14651858.CDoo3468. Cited in PubMed: PMID: 12535476.
   Google Scholar
• Arciniegas DB, Topkoff J, Silver JM. 2000. Neuropsychiatric aspects of traumatic brain injury. Curr Treatments Options Neurol 2:169–86. Cited in PubMed: PMID: 11096746.
   PubMedGoogle Scholar
• Chew E, Zafonte RD. Pharmacological management of neurobehavioural disorders following traumatic brain injury–a state-of-the-art review. J Rehabil Res Dev. 2009;46(6):851–79. Cited in PubMed: PMID: 12676415.
   PubMed Web of Science ®Google Scholar
• Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj. Cited in PubMed: PMID: 14660233 2004 Jan;18(1):1–31. doi: 10.1080/0269905031000110463.
   PubMed Web of Science ®Google Scholar
• Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006. Oct 18;(4):CD003299. doi:10.1002/14651858.CD003299.pub2. Cited in PubMed; PMID: 17054165.
   PubMed Web of Science ®Google Scholar
• Leone H, Polsonetti BW. Amantadine fort traumatic brain injury: does it improve cognition and reduce agitation? J Clin Pharm Ther. Cited in PubMed: PMID: 15811161 2005 Apr;30(2):101–04. doi: 10.1111/j.1365-2710.2005.00628.x.
   PubMed Web of Science ®Google Scholar
• Levy M, Berson A, Cook T, Bollegala N, Seto E, Tursanski S, Kim J, Sockalingam S, Rajput A, Krishnadev N, et al. Treatment of agitation following traumatic brain injury: a review of the literature. Neurorehabil. 2005 Cited in PubMed: PMID: 16403996;20(4):279–306.
   PubMed Web of Science ®Google Scholar
• Warden DL, Warden DL, Gordon B, McAllister TW, Silver JM, Barth JT, Bruns J, Drake A, Gentry T, Jagoda A, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. Cited in PubMed: PMID: 17020483 2006 Oct;23(10):1468–501. doi: 10.1089/neu.2006.23.1468.
   PubMed Web of Science ®Google Scholar
• Lane-Brown A, Tate R. Interventions for apathy after traumatic brain injury (review). Cochrane Database Syst Rev. 2009;(2):CD006341. doi:10.1080/09602010902949207. Cited in PubMed: PMID: 19533496.
   PubMed Web of Science ®Google Scholar
• Karli DC, Burke DT, Kim HJ, CALVANIO R, FITZPATRICK M, TEMPLE D, MACNEIL M, PESEZ K, LEPAK P. Case study: effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj. 1999 Cited in PubMed: 9972445;13:63–68. doi:10.1080/026990599121908.
   PubMed Web of Science ®Google Scholar
• Sami MB, Faruqui R. The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke. Acta Neuropsychiatr. 2015 Apr 8;1–11. doi:10.1017/neu.2015.17. Cited in PubMed: PMID: 25850757.
   Web of Science ®Google Scholar
• Hammond FM, Bickett AK, Norton JH, Pershad R. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. 2014;29(5):391–99. doi:10.1097/01.HTR.0000438116.56228.de. Cited in PubMed: PMID: 24263176.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med;6(7):e1000097. doi:10.1371/journal.pmed.1000097. Cited in PubMed: PMID: 19621072.
   PubMed Web of Science ®Google Scholar
• Spieth PM, Kubash AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T. Randomized controlled trials – a matter of design. Neuropsychiatr Dis Treat. 2016 jun 10;12:1341–49. doi: 10.2147/NDT.S101938. Cited in PubMed: PMID: 27354804
   PubMed Web of Science ®Google Scholar
• Quality Assessment Tool for Quantitative Studies (QATFQS) from the Effective Public Health Practice Project. 2007 (EPHPP) (Thomas, Ciliska, Dobbins, & Micucci, 2004, Deeks et al., 2003).
   Google Scholar
• Tate RL, McDonald S, Perdices M, Togher L, Schultz R, Savage S. Rating the methodological quality of single-subject designs and n-of-1 trials: introducing the Single-Case Experimental Design (SCED) scale. Neuropsychol Rehabil. 2008;18(4):385–401. doi:10.1080/09602010802009201. Cited in PubMed: PMID: 18576270.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Sherer M, Malec JF, Zafonte RD, Whitney M, Bell K, Dikman S, Bogner J, Mysiw J, Pershad R. Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma. 2015 Aug 15;32(16):1230–38. doi: 10.1089/neu.2014.3803. Cited in PubMed: PMID: 25774566
   PubMed Web of Science ®Google Scholar
• Hammond FM, Malec JF, Zafonte RD, Sherer M, Bogner J, Dikmen S, Whitney MP, Bell KR, Perkins SM, Moser EA. Potential impact of amantadine on aggression in chronic brain injury. J Head Trauma Rehabil. Cited in PubMed: PMID: 28891908 2017 Sep/Oct;32(5):308–18. doi: 10.1097/HTR.0000000000000342.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Sherer M, Malec JF, Zafonte RD, Dikmen S, Bogner J, Bell KR, Barber J, Temkin N. Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized controlled trial. J Neurotrauma. 2018 Oct 01;35(19):2298–305. doi: 10.1089/neu.2018.5767. Cited in PubMed: PMID: 29742960
   PubMed Web of Science ®Google Scholar
• Schneider WN, Drew-Cates WJ, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study, Cited in PubMed: PMID: 10579658. Brain Inj. Nov 1999;13(11):863–72.
   PubMed Web of Science ®Google Scholar
• Reekum RV, Bayley M, Garner S, Burke IM, Fawsett S, Hart A, Thompson W. 1995. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 9:49–53. Cited in PubMed: PMID: 7874096.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. Cited in PubMed: PMID: 9144101 1997;9(2):222–30. Spring. doi: 10.1176/jnp.9.2.222.
   PubMed Web of Science ®Google Scholar
• Arciniegas DB, Frey KL, Anderson CA, Brousseau KM, Harris SN. Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy, Cited in PubMed: OMID: 15666573. Brain Inj. Dec 2004;18(12):1309–18.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Maki P. The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury, Cited in PubMed: PMID: 9171930. Brain Inj. Jun 1997;11(6):455–60.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET), Cited in PubMed: PMID: 16134735. Brain Inj. Jul 2005;19(7):471–79.
   PubMed Web of Science ®Google Scholar
• Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation, Cited in PubMed: PMID: 7849690. Brain Inj. Nov-Dec 1994;8(8):709–18.
   PubMed Web of Science ®Google Scholar
• Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, McDonald S. Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: the 15-item risk of bias in N-of-1 trials (RoBiNT) scale. Neuropsychol Rehabil. 2013;23(5):619–38. doi:10.1080/09602011.2013.824383. Cited in PubMed: PMID: 24050810.
   PubMed Web of Science ®Google Scholar
• Perdices M, Tate RL. Single-subject designs as a tool for evidence-based clinical practice: are they unrecognised and undervalued? Neuropsychol Rehabil. 2009;19(6):904–27. doi:10.1080/09602010903040691. Cited in PubMed: PMID:19657974.
   PubMed Web of Science ®Google Scholar
• Barlow DH, Nock MK, Hersen M. Single case experimental designs. Strategies for studying behavior change. Third ed. New York: Pearson Education, Inc; 2009.
   Google Scholar
• Stunnenberg BC, Woertman W, Raaphorst J, Statland JM, Griggs RC, Timmermans J, Saris CG, Schouwenberg BJ, Groenewoud HM, Stegeman DF, et al. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurol;2015. Open access. doi:10.1186/s12883-015-0294-4. Cited in PubMed: PMID: 25880166.
   PubMed Web of Science ®Google Scholar
• Zucker DR, Schmid CH, McIntosh MW, D’Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treament effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50(4):401–10. Cited in PubMed: PMID: 9179098.
   PubMed Web of Science ®Google Scholar
• Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, Mogavero N, Rapoport RJ, Selker HP, Stotsky SA, et al. Lessons learned combining N-of-1 trials to access fibromyalgie therapies. J Rheumatol. 2006;33:2069–77. Cited in PubMed: PMID: 17014022.
   PubMed Web of Science ®Google Scholar